Unlocking Q4 Potential of Tandem Diabetes Care (TNDM): Exploring Wall Street Estimates for Key Metrics

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is expected to report a quarterly loss of -$0.05 per share, marking an 88.6% increase in loss compared to the same period last year [1] - Analysts forecast revenues of $276 million, reflecting a year-over-year increase of 9.3% [1] - The consensus EPS estimate has been adjusted downward by 0.8% over the past 30 days, indicating a reassessment by covering analysts [1] Revenue Estimates - Analysts project 'Revenue- Supplies and Other' to reach $141.55 million, indicating a year-over-year change of +10.4% [4] - The consensus for 'Revenue- Pump' is estimated at $134.50 million, showing an increase of +8.3% from the prior-year quarter [4] - 'Sales- Pump- United States' is expected to be $108.34 million, reflecting a year-over-year change of +10.1% [4] Geographic Sales Projections - 'Sales- Pump- Outside the United States' is estimated to be $26.16 million, indicating a +1.5% change from the year-ago quarter [5] - 'Sales- Supplies and Other- United States' is forecasted to reach $94.74 million, with a year-over-year change of +10.3% [5] - The estimated 'Geographic Sales- United States' stands at $203.09 million, reflecting a year-over-year change of -5.4% [5] International Sales Estimates - 'Sales- Supplies and Other- Outside the United States' is projected at $46.80 million, indicating a +10.6% change from the prior-year quarter [6] - The consensus for 'Geographic Sales- Outside the United States' is $72.94 million, showing a significant decline of -99.9% from the year-ago quarter [6] Pump Shipments Forecast - Total worldwide 'Pump Shipments' are expected to reach 35,032, compared to 34,000 in the same quarter last year [7] - 'Pump Shipments- Outside the United States' is projected at 9,400, down from 10,000 in the previous year [7] - 'Pump Shipments- United States' is estimated at 25,632, compared to 24,000 in the year-ago period [7] Stock Performance - Over the past month, shares of Tandem Diabetes Care have returned -6%, while the Zacks S&P 500 composite has changed by -1.4% [8] - TNDM currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]